31,145 Shares in Becton, Dickinson and Company $BDX Bought by First Nebraska Trust Co

First Nebraska Trust Co purchased a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 31,145 shares of the medical instruments supplier’s stock, valued at approximately $5,575,000.

Several other hedge funds also recently modified their holdings of BDX. Maryland Capital Advisors Inc. boosted its stake in Becton, Dickinson and Company by 13,900.0% during the third quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 139 shares in the last quarter. Meeder Asset Management Inc. grew its holdings in Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 102 shares during the period. Main Street Group LTD bought a new stake in Becton, Dickinson and Company in the first quarter worth about $29,000. Bell Investment Advisors Inc bought a new stake in Becton, Dickinson and Company in the second quarter worth about $29,000. Finally, Kelleher Financial Advisors acquired a new stake in Becton, Dickinson and Company in the 2nd quarter valued at about $30,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the transaction, the executive vice president owned 19,720 shares in the company, valued at approximately $3,717,022.80. The trade was a 0.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the transaction, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. This represents a 14.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 6,907 shares of company stock worth $1,269,128 over the last quarter. Corporate insiders own 0.40% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on BDX shares. Wolfe Research started coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, October 20th. They set an “outperform” rating for the company. Piper Sandler boosted their target price on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. UBS Group began coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, July 28th. They set a “buy” rating and a $190.00 target price for the company. Stifel Nicolaus set a $195.00 target price on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Finally, Barclays started coverage on shares of Becton, Dickinson and Company in a report on Wednesday, October 7th. They set an “underweight” rating and a $165.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $185.07.

Becton, Dickinson and Company Stock Down 0.4%

BDX stock opened at $197.88 on Wednesday. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $200.47. The company’s 50 day simple moving average is $186.86 and its 200-day simple moving average is $170.20. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The firm has a market capitalization of $54.52 billion, a P/E ratio of 59.60, a P/E/G ratio of 13.39 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same quarter last year, the business posted $3.68 EPS. The company’s revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.